WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive ...

Presented by AstraZeneca{beacon} Health Care Health Care   The Big Story CMS targets hospitals with site-neutral drug ruleThe ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...

Newly published research claims those taking GLP-1 jabs are at a 37 percent lower risk of dementia than those on the anti-diabetic medication.

Roughly 16 million American adults are taking GLP-1 medications. They are a major breakthrough for people to shed pounds and ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...

New research published Tuesday concludes that the rising rate of extreme childhood obesity—well above the usual BMI ...

Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected Q3 ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

Biocon plans to launch generic copies of Wegovy in India and Canada within two years, targeting a growing drug market ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, the ...